Aragon Pharmaceuticals, Inc.

This study provided early access to the drug apalutamide for men with a specific type of advanced prostate cancer that had stopped responding to standard hormone therapy but had not yet spread to other parts of the body. The main goal was to collect safety information while the d…

This large, late-stage study tested whether adding a new drug called apalutamide to standard hormone therapy works better for men whose prostate cancer has spread. Over 1,000 participants were randomly assigned to receive either the new combination or standard therapy plus a plac…

This large study is testing whether adding a new drug called apalutamide to standard radiation and hormone therapy helps men with high-risk prostate cancer. It aims to see if this combination keeps the cancer from spreading to other parts of the body for a longer time. The trial …

This large Phase 3 trial tested whether the drug apalutamide (ARN-509) could delay the spread of prostate cancer in men whose cancer had stopped responding to standard hormone therapy but hadn't yet spread to other body parts. About 1,200 men were randomly assigned to receive eit…

This large, late-stage study tested whether adding a new drug called apalutamide to a standard two-drug therapy could better control advanced prostate cancer that has spread and stopped responding to hormone therapy. It involved nearly 1,000 men whose cancer had not yet been trea…

This early-stage study is checking how two prostate cancer drugs, JNJ-56021927 and abiraterone acetate, interact in the body when taken together. It involves 57 men whose prostate cancer has spread and is no longer responding to standard hormone-blocking treatments. The main goal…

This study aims to understand how a prostate cancer drug called JNJ-56021927 affects the way the body processes other common medications. It involves 23 men with advanced prostate cancer that no longer responds to standard hormone therapy. Researchers are measuring drug levels in…